Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine (Articolo in rivista)

Type
Label
  • Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine (Articolo in rivista) (literal)
Anno
  • 2013-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1093/infdis/jit114 (literal)
Alternative label
  • Tang M.W.; Rhee S.-Y.; Bertagnolio S.; Ford N.; Holmes S.; Sigaloff K.C.; Hamers R.L.; De Wit T.F.R.; Fleury H.J.; Kanki P.J.; Ruxrungtham K.; Hawkins C.A.; Wallis C.L.; Stevens W.; Van Zyl G.U.; Manosuthi W.; Hosseinipour M.C.; Ngo-Giang-Huong N.; Belec L.; Peeters M.; Aghokeng A.; Bunupuradah T.; Burda S.; Cane P.; Cappelli G.; Charpentier C.; Dagnra A.Y.; Deshpande A.K.; El-Katib Z.; Eshleman S.H.; Fokam J.; Gody J.-C.; Katzenstein D.; Koyalta D.D.; Kumwenda J.J.; Lallemant M.; Lynen L.; Marconi V.C.; Margot N.A.; Moussa S.; Ndung'U T.; Nyambi P.N.; Orrell C.; Schapiro J.M.; Schuurman R.; Sirivichayakul S.; Smith D.; Zolfo M.; Jordan M.R.; Shafer R.W. (2013)
    Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine
    in The Journal of infectious diseases
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Tang M.W.; Rhee S.-Y.; Bertagnolio S.; Ford N.; Holmes S.; Sigaloff K.C.; Hamers R.L.; De Wit T.F.R.; Fleury H.J.; Kanki P.J.; Ruxrungtham K.; Hawkins C.A.; Wallis C.L.; Stevens W.; Van Zyl G.U.; Manosuthi W.; Hosseinipour M.C.; Ngo-Giang-Huong N.; Belec L.; Peeters M.; Aghokeng A.; Bunupuradah T.; Burda S.; Cane P.; Cappelli G.; Charpentier C.; Dagnra A.Y.; Deshpande A.K.; El-Katib Z.; Eshleman S.H.; Fokam J.; Gody J.-C.; Katzenstein D.; Koyalta D.D.; Kumwenda J.J.; Lallemant M.; Lynen L.; Marconi V.C.; Margot N.A.; Moussa S.; Ndung'U T.; Nyambi P.N.; Orrell C.; Schapiro J.M.; Schuurman R.; Sirivichayakul S.; Smith D.; Zolfo M.; Jordan M.R.; Shafer R.W. (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://www.scopus.com/inward/record.url?eid=2-s2.0-84878329003&partnerID=q2rCbXpz (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 207 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 2 (literal)
Note
  • Scopu (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Division Infectious Diseases, Department of Medicine, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, United States; WHO/HTM/TCO, Geneva, Switzerland; Department of Statistics, Stanford University, CA, United States; PharmAccess Foundation, Department of Global Health, Academic Medical Center of the University of Amsterdam, Netherlands; Laboratoire de Virologie (WHO Accredited), CHU de Bordeaux, Bordeaux, France; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, United States; Department of Medicine, Chulalongkorn University, Thai Red Cross AIDS Research Center, Bangkok, Thailand; Northwestern University, Chicago, IL, United States; Lancet Laboratories, Johannesburg, South Africa; Department of Molecular Medicine and Haematology, University of the Witwatersrand, National Laboratory Health Services, Johannesburg, South Africa; Division of Medical Virology, Stellenbosch University, Tygerberg, Cape Town, South Africa; Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand; University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi; Institut de Recherche Pour le Developpement IRD U174, Program for HIV Prevention and Treatment, Chiang Mai, Thailand; Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Université Paris Descartes, 75908 Paris Cedex 15, Paris, France; UMI233, Institut de Recherche Pour le Développement (IRD), Université Montpellier 1, Montpellier, France; Virology Laboratory CREMER/IMPM/IRD, Yaoundé, Cameroon; HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, New York, NY, United States; Department of Pathology, New York University School of Medicine, New York, NY, United States; Health Protection Agency, London, United Kingdom; Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon; National Research Council, Rome, Italy; Laboratoire de Virologie, Groupe Hospitalier Bichat-Claude Bernard, Université Paris Diderot, EA4409 Paris, France; Centre National de Référence des Tests VIH-IST/PNLS and Laboratoire BIOLIM, FMMP/UL, Lomé, Togo; ART Center, Sir JJ Hospital, Byculla, Mumbai, India; Division of Cancer Epidemiology, McGill University, Montreal, Canada; Division of Global Health (IHCAR), Karolinska Institute, Stockholm, Sweden; Dept. of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Faculty of Medicine and Biomedical Sciences (FMBS) of the University of Yaounde 1, Yaounde, Cameroon; Faculté des Sciences de la Santé Bangui, République Centrafricaine, N'Djamena, Chad; Complexe Pédiatrique Bangui, République Centrafricaine, N'Djamena, Chad; Hôpital Général de Référence Nationale, N'Djamena, Chad; Dept. of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi; Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Institute of Tropical Medicine (ITM), Antwerp, Belgium; Emory University School of Medicine, Atlanta, GA, United States; Rollins School of Public Health, Emory University, Atlanta, GA, United States; Gilead Sciences Inc., Foster City, CA, United States; Unité des Rétrovirus et des Virus Oncogènes, Institut Pasteur de Bangui, Bangui, Central African Republic; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Department of Pathology, New York University, School of Medicine, New York, NY, United States; Veterans Affairs New York Harbor Healthcare Systems, New York, NY, United States; Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; National Hemophilia Center, Tel Hashomer, Israel; Department of Virology, University Medical Center Utrecht, Netherlands; Division of Infectious Diseases, University of California San Diego, San Diego, CA, United States; Veterans Affairs Healthcare System San Diego, San Diego, CA, United States; Tufts University School of Medicine, Boston, MA, United States (literal)
Titolo
  • Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine (literal)
Abstract
  • Background The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary candidates for replacing stavudine. However, because resistance testing is rarely available in resource-limited settings, it is critical to identify the cross-resistance patterns associated with first-line stavudine failure.MethodsWe analyzed HIV-1 resistance mutations following first-line stavudine failure from 35 publications comprising 1,825 individuals. We also assessed the influence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 subtype on the proportions of mutations associated with zidovudine vs. tenofovir cross-resistance.ResultsMutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of individuals. Mutations with preferential tenofovir activity, >=two thymidine analog mutations (TAMs) or Q151M, occurred in 22% of individuals. Nevirapine increased the risk of TAMs, K65R, and Q151M. Longer therapy increased the risk of TAMs and Q151M but not K65R. Subtype C and CRF01-AE increased the risk of K65R, but only CRF01-AE increased the risk of K65R without Q151M.ConclusionsRegardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype, tenofovir was more likely than zidovudine to retain antiviral activity following first-line d4T therapy. © The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it